GENE-THERAPEUTIC DNA-VECTOR BASED ON GENE-THERAPEUTIC DNA-VECTOR VTVAF17, CARRYING TARGET GENE SELECTED FROM GROUP OF GENES NOS2, NOS3, VIP, KCNMA1, CGRP, TO INCREASE EXPRESSION LEVEL OF THESE TARGET GENES, METHOD FOR PRODUCTION AND USE THEREOF, STRAIN ESCHERICHIA COLI SCS110-AF/VTVAF17-NOS2, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-NOS3, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-VIP, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-KCNMA1, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-CGRP, CARRYING GENE-THERAPEUTIC DNA VECTOR, METHOD FOR PRODUCTION THEREOF, METHOD FOR INDUSTRIAL PRODUCTION OF GENE-THERAPEUTIC DNA VECTOR

摘要

FIELD: biotechnology; medicine; agriculture.;SUBSTANCE: invention refers to genetic engineering and can be used in biotechnology, medicine and agriculture to develop gene therapy preparations. Presented is a gene-therapeutic DNA vector based on a gene-therapeutic DNA vector VTvaf17, carrying a target gene selected from a group of genes NOS2, NOS3, VIP, KCNMA1, CGRP, to increase expression level of this target gene in human body and animals. Gene-therapeutic DNA vector VTvaf17-NOS2, or VTvaf17-NOS3, or VTvaf17-VIP, or VTvaf17-KCNMA1, or VTvaf17-CGRP has a nucleotide sequence SEQ ID No. 1 or SEQ ID No. 2 or SEQ ID No. 3 or SEQ ID No. 4 or SEQ ID No. 5, respectively. Invention also discloses a method of producing said vector, use of a vector, an Escherichia coli strain carrying said vector, as well as a method of producing said vector on an industrial scale.;EFFECT: invention can be used for safe application for human and animal genetic therapy.;16 cl, 22 ex, 16 dwg